For men weighing a prostate blood test against extra biopsies: how the ages split, and which result still needs a second test before anyone mentions a biopsy.
A society that last wrote this advice in 2010 has published a new prostate-screening guideline. It appeared in CA: A Cancer Journal for Clinicians and was indexed on PubMed on 12 November 2026 (Hoffman RM et al., PMID 43018083). For named groups of men the panel now sets a PSA blood test on a calendar. The 2010 document, by the same society, told clinicians to offer an informed decision and did not set that calendar (Wolf AM et al., PMID 20200110).
This page is information for readers. It does not replace a consultation with a doctor.
What is a PSA number, in ordinary terms?
PSA is a protein measured in blood. A higher reading can come from prostate cancer, and also from a large prostate, inflammation, or a recent disturbance of the gland. The 2026 guideline treats the test as a first step: repeat the blood test, then often a scan or another marker, then decide on a biopsy. The number is not a diagnosis.
Who is on a two-year schedule, and who is on a yearly one?
For men the panel calls average risk — men who are not Black and who have no family history of prostate cancer — the recommendation is a PSA test every 2 years from age 50 through 69. The line is graded B, with moderate certainty: in this guideline that means a net benefit for most people in the named group, not a forecast for one man.
Black men — men who identify as Black or African American, in the guideline's words — are advised to start at 45 and test every year through 69. The starting age is graded B, with low certainty. The yearly interval is a consensus statement: agreed from evidence, models and judgment, without a formal evidence grade.
Non-Black men with a strong family history are on that same yearly schedule from 45 through 69. Strong means more than one first-degree relative — father, brother or son — diagnosed at any age, or one diagnosed before 65. That line is a consensus statement.
If the only first-degree relative was diagnosed at 65 or older, the panel's consensus is every 2 years from 45 through 69, not every year.
These lines do not apply to men with a known or suspected hereditary cancer syndrome, including a BRCA2 mutation. The guideline points those men to specialty advice, including guidance from the American Urological Association and the National Comprehensive Cancer Network.
What did the long European trial actually count?
The mortality figures the panel relies on come from the European Randomized Study of Screening for Prostate Cancer. The 23-year update is in The New England Journal of Medicine (Roobol MJ et al., 2025, PMID 41160819). A predefined core of 162,236 men, aged 55 to 69 at randomisation, was followed across eight European countries. One group was invited to repeated PSA testing. The other was not invited.
After a median of 23 years, prostate-cancer mortality was lower in the invited group. The rate ratio was 0.87 (95% confidence interval 0.80 to 0.95). The absolute difference was 0.22 percentage points (95% CI 0.10 to 0.34). The authors calculated that one prostate-cancer death was averted for every 456 men invited (95% CI 306 to 943). Diagnoses moved the other way. Cumulative incidence of prostate cancer was higher in the invited group, with a rate ratio of 1.30 (95% CI 1.26 to 1.33). The trial was funded by the Dutch Cancer Society and others. The registry number is ISRCTN49127736.
That rate ratio is not a forecast for one man booking a test. Invited men and men who attended are not the same set, the comparison group was not offered the test, and care after a high PSA has changed since 1993. The guideline also describes the US PLCO trial, which did not find fewer prostate-cancer deaths when screening included a rectal examination, and treats the result as hard to read because many men in the comparison group had PSA tests outside the trial.
On US registry figures, the same paper says men who identify as Black have about 67% higher prostate-cancer incidence and nearly double the mortality of White men. A SEER analysis for 2005–2021, cited there, has metastatic disease rising from 16 to 22 per 100,000 in Black men and from 6 to 11 per 100,000 in White men. The paper says the gap may reflect stage, biology, access and differences in screening and treatment. A higher population rate does not show that a yearly test closes it for one man.
What a reading above the cutoff does not settle
The panel names a level that should be checked again before further work: 3.0 ng/mL or higher for men aged 69 and younger, and 6.5 ng/mL or higher for men aged 70 to 74. The repeat test is preferably 2 weeks to 3 months after the first. That timing is a consensus statement.
For most men whose second test is still high, the panel says offer magnetic resonance imaging, a validated biomarker, or both, before deciding on a biopsy. A urologist may go straight to biopsy in some situations, for example a suspicious rectal examination or a markedly high PSA. The rectal examination itself is not recommended as the screening test. That line is graded D, with high certainty.
If a low-risk cancer is found, the panel says offer active surveillance first, not immediate treatment. That is a consensus statement: watch a lower-risk cancer and defer treatment unless the risk is reclassified. It is not a claim that the cancer is harmless.
What to do if a PSA test is on your mind
From 70 through 74 the panel calls the balance uncertain and recommends an individual decision. That line is graded C, with low certainty. If a man in that window chooses screening, the guideline says every 2 years through 74, and that screening may stop after any PSA below 3 ng/mL.
Screening is not recommended at 75 or older, or at any age when life expectancy is under 10 years. That line is graded D, with low certainty. The panel asks clinicians to say when and why they are stopping.
Before the first test the guideline still expects a talk about what the test can show, what a high result can lead to, and that a low-risk cancer would start on surveillance. Nothing here is a reason to start, stop or change a test or a treatment on your own. Discuss the guideline with a doctor.
A blood panel used before MRI when PSA sits between 1.8 and 3 ng/mL in the Göteborg-2 trial is a different question: 4Kscore before MRI at a low PSA.
Sources
Hoffman RM, Wolf AMD, Etzioni RD, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA: A Cancer Journal for Clinicians. 2026. PMID 43018083. DOI 10.3322/caac.70112.
Roobol MJ, de Vos II, Månsson M, et al. European Study of Prostate Cancer Screening — 23-year follow-up. The New England Journal of Medicine. 2025. PMID 41160819. DOI 10.1056/NEJMoa2503223.
Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA: A Cancer Journal for Clinicians. 2010. PMID 20200110. DOI 10.3322/caac.20066.
ISRCTN registry. ISRCTN49127736, European Randomized Study of Screening for Prostate Cancer. Registry record.
Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.
Read next
ResearchMedicine and treatmentA tau antibody missed its main Alzheimer's score
For anyone following Alzheimer's research: what a phase 2 trial found on the score clinicians use to track daily function, and which questions that result leaves open.
ResearchMedicine and treatmentEarly TB treatment and an esophageal cancer drug — plus 2 stories
4 stories this week: severe pneumonia in infants with HIV, esophageal cancer after a first treatment line, blood pressure and memory in type 2 diabetes, and a heart-rhythm ablation. Each note names who was studied and where the result stops.
Digest · 4 stories
ResearchMedicine and treatmentThe busiest minute of the day lined up with fewer deaths
For a reader who already moves on ordinary days and still cannot tell which part of that day is worth a conversation with a doctor. Inside is a comparison of people as they already were, not a plan for the next week.
